Vericiguat: A New Hope for Heart Failure Patients

Table 1

Treatment effect for the primary composite endpoint and the secondary endpoints of cardiovascular death and heart failure hospitalization.

	Placebo		Vericiguat		Treatment comparison
	(%)	Event rate: % of patients/year^1	(%)	Event rate: % of patients/year^1	Hazard ratio (95% CI)^2	value^3	Absolute risk reduction^4
Primary endpoint
Composite of cardiovascular death or heart failure hospitalization^5	972 (38.5)	37.8	897 (35.5)	33.6	0.90 (0.82, 0.98)	0.019	4.2
Secondary endpoints
Cardiovascular death	441 (17.5)	13.9	414 (16.4)	12.9	0.93 (0.81, 1.06)
Heart failure hospitalization	747 (29.6)	29.1	691 (27.4)	25.9	0.90 (0.81, 1.00)

¹Total patients with an event per 100 patient years at risk. ²Hazard ratio (VERQUVO over placebo) and confidence interval from a Cox proportional hazards model. ³From the log-rank test. ⁴Absolute risk reduction, calculated as difference (placebo-VERQUVO) in event rate per 100 patient years. ⁵For patients with multiple events, only the first event contributing to the composite endpoint is counted. = number of patients in intent-to-treat (ITT) population; = number of patients with an event.